What Does Generalizable AI in Drug Discovery Really Mean?

Machine learning models increasingly contribute to drug discovery, but their utility depends on performing reliably in their intended deployment setting. Although model generalization is invoked frequently, the drug discovery community lacks a shared vocabulary for how models actually achieve transferability beyond their training data. We argue that achieving generalization requires examining how a model’s inductive bias interacts with its training data to shape the notion of similarity it learns. Without a bias that makes relevant recurring relationships easier to learn as opposed to incidental correlations, models exploit dataset-specific shortcuts. These shortcuts yield high benchmark performance but fail in prospective applications. We therefore propose evaluation principles tailored to a model’s architecture, using diagnostic controls and train−test splits that distinguish transferable learning from the retrieval of familiar training data. This Perspective shows how representational choices shape failure modes across pose-dependent, pose-independent, and foundation model paradigms, and provides a practical framework to help researchers expose shortcuts and interpret predictions.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-18
DOI
https://doi.org/10.1021/acs.jmedchem.6c01918
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

What Does Generalizable AI in Drug Discovery Really Mean?

Benjamin P. Brown
2 links
Journal of Medicinal Chemistry
Computational Drug Discovery Methods
article

What Does Generalizable AI in Drug Discovery Really Mean?

Benjamin P. Brown
article en

Abstract

Machine learning models increasingly contribute to drug discovery, but their utility depends on performing reliably in their intended deployment setting. Although model generalization is invoked frequently, the drug discovery community lacks a shared vocabulary for how models actually achieve transferability beyond their training data. We argue that achieving generalization requires examining how a model’s inductive bias interacts with its training data to shape the notion of similarity it learns. Without a bias that makes relevant recurring relationships easier to learn as opposed to incidental correlations, models exploit dataset-specific shortcuts. These shortcuts yield high benchmark performance but fail in prospective applications. We therefore propose evaluation principles tailored to a model’s architecture, using diagnostic controls and train−test splits that distinguish transferable learning from the retrieval of familiar training data. This Perspective shows how representational choices shape failure modes across pose-dependent, pose-independent, and foundation model paradigms, and provides a practical framework to help researchers expose shortcuts and interpret predictions.

Journal of Medicinal Chemistry
Vanderbilt University (US)
Vanderbilt University, Baldwin Wallace University, National Institutes of Health, National Institute on Drug Abuse
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon